7:45-8:00 a.m.
Welcome
Dan Blazer, Committee Chair
8:00-9:30 Panel 1: Testosterone Levels and Aging
8:00
Natural History of Testosterone Levels with Aging
William Bremner, University of Washington
8:15
Correlation of Testosterone Changes and Clinical Outcomes
S. Mitchell Harman, Kronos Longevity Research Institute
12:10-12:40
Discussion, Moderated by Darracott Vaughan
12:40-1:30 Lunch
1:30-3:00 Panel 4: Cognitive, Sexual Function, Mood, and Quality of Life Outcomes
1:30
Biological Plausibility and Brain Targets for Androgens
Jeri Janowsky, Oregon Health and Science University
1:45
Androgen Effects on Cognition
Monique Cherrier, University of Washington
2:00
Sexual Function, Mood, and Quality of Life Outcomes in Testosterone Replacement Studies
Ronald Swerdloff, University of California, Los Angeles
2:15
Measurement of Sexual Function, Mood, and Quality of Life Endpoints in Older Men
Raymond Rosen, Robert Wood Johnson Medical School
2:30-3:00
Discussion, Moderated by Leslie Schover
3:05-4:10 Panel 5: Hematologic and Cardiovascular Outcomes
3:05
Hematologic and Cardiovascular Outcomes in Testosterone Replacement Studies
Adrian Dobs, Johns Hopkins University
3:20
Testosterone, Inflammation, and Clotting
Russell Tracy, University of Vermont
3:35-4:10
Discussion, Moderated by Elizabeth Barrett-Connor
4:10-4:30 Break
4:30-5:15
Perspective from Studies of Postmenopausal Hormone Therapy
Ross Prentice, Fred Hutchinson Cancer Research Center
4:50-5:15
Discussion, Moderated by Steve Lagakos
5:15-6:15 Perspectives from the Pharmaceutical Industry
5:15
Extent and Nature of Testosterone Use
Kevin Rose, Solvay Pharmaceuticals, Inc.
Clinical Experience with AndroGel
Hjalmar Lagast, Solvay Pharmaceuticals, Inc.
5:45-6:15
Discussion, Moderated by Dan Blazer